NCT05254327View on ClinicalTrials.gov

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

PHASE2RecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

May 31, 2027

Study Completion Date

June 30, 2029

Conditions
Rectal Cancer
Interventions
DRUG

BMX-001

Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.

Trial Locations (3)

40536

RECRUITING

Markey Cancer Center, Lexington

68198

RECRUITING

University of Nebraska Medical Center, Omaha

78229

RECRUITING

UT Health San Antonio MD Anderson Cancer Center, San Antonio

Sponsors

Collaborators (1)

BioMimetix JV, LLC
All Listed Sponsors
collaborator

BioMimetix JV, LLC

INDUSTRY

lead

University of Nebraska

OTHER

NCT05254327 - Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 | Biotech Hunter | Biotech Hunter